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Abstract
Background: SET/I2PP2A is a multifunctional protein that is up-regulated in head and neck squamous cell
carcinoma (HNSCC). The action of SET in HNSCC tumorigenicity is unknown.
Methods: Stable SET knockdown by shRNA (shSET) was established in three HNSCC cell lines: HN12, HN13, and
Cal27. Protein expression and phosphorylated protein levels were determined by Western blotting and
immunofluorescence, cell migration and invasion were measured by functional analysis, and PP2A activity was
determined using a serine/threonine phosphatase assay. A real-time PCR array was used to quantify 84 genes
associated with cell motility. Metalloproteinase (MMP) activity was assessed by zymographic and fluorometric assays.
HN12shSET xenograft tumors (flank and tongue models) were established in Balb/c nude mice; the xenograft
characteristics and cisplatin sensitivity were demonstrated by macroscopic, immunohistochemical, and histological
analyses, as well as lymph node metastasis by histology.
Results: The HN12shSET cells displayed reduced ERK1/2 and p53 phosphorylation compared with control. ShSET
reduced HN12 cell proliferation and increased the sub-G1 population of HN12 and Cal27 cells. Increased PP2A
activity was also associated with shSET. The PCR array indicated up-regulation of three mRNAs in HN12 cells:
vimentin, matrix metalloproteinase-9 (MMP9) and non-muscle myosin heavy chain IIB. Reduced E-cadherin and
pan-cytokeratin, as well as increased vimentin, were also demonstrated as the result of SET knockdown. These
changes were accompanied by an increase in MMP-9 and MMP-2 activities, migration and invasion. The HN12shSET
subcutaneous xenograft tumors presented a poorly differentiated phenotype, reduced cell proliferation, and
cisplatin sensitivity. An orthotopic xenograft tumor model using the HN12shSET cells displayed increased metastatic
potential.
Conclusions: SET accumulation has important actions in HNSCC. As an oncogene, SET promotes cell proliferation,
survival, and resistance to cell death by cisplatin in vivo. As a metastasis suppressor, SET regulates invasion, the
epithelial mesenchymal transition, and metastasis.
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Introduction
SET (I2PP2A) is a 39 kDa phosphoprotein encoded by the
SET gene. SET was originally identified as a component of
the SET-CAN fusion gene produced by somatic transloca-
tion in acute, undifferentiated leukemia [1]. SET is a po-
tent and specific inhibitor of protein phosphatase 2A
(PP2A) [2], a serine/threonine phosphatase involved in the
regulation of cell proliferation, differentiation, and trans-
formation. SET-mediated PP2A inhibition occurs via de-
phosphorylation of proteins, such as the extracellular
signal-regulated kinase (ERK) [3] and protein kinase B
(Akt) [4]. Recently, we demonstrated that SET accumu-
lates in head and neck squamous cell carcinoma (HNSCC)
and suggested a new role for SET as a sensor of oxidative
stress, thereby promoting cell survival in association with
increased phosphorylated Akt levels and an enhanced
antioxidant defense [5].
The mitogen-activated protein kinases (MAPKs) trans-
duce signals from the cell membrane to the nucleus in
response to a wide range of stimuli. MAPKs include
three family members: ERKs (ERK1 and ERK2), c-Jun
NH2-terminal kinase (JNK), and p38MAPK. ERKs are
activated by phosphorylation and translocation to the
nucleus where they phosphorylate multiple substrates
[6]. It has been proposed that SET is a negative regula-
tor of cell growth in response to external stimuli
through inhibition of the MEK/ERK pathway and the
G1/S transition [7].
The p53 protein is a tumor suppressor that protects
the genome by preventing cell transformation and indu-
cing cell cycle arrest, DNA repair, and apoptosis. p53
phosphorylation is required for signal transduction in re-
sponse to DNA damage and p21 protein activation [8,9].
Indeed, SET interacts with p21 [10] and modulates p53
and Akt mRNA levels in Alzheimer’s disease neurons
[11]. Of particular interest, the p53 protein is also in-
volved in the epithelial-mesenchymal transition (EMT)
[12]. The EMT promotes a mesenchymal-like phenotype
in cells, that is characterized by enhanced migratory
ability, invasion, and metastasis. The transmembrane
protein E-cadherin is a molecular marker expressed in
epithelial cells [13], and the loss of E-cadherin expres-
sion is positively correlated with tumor stage and grade.
In the EMT, epithelial cells down-regulate E-cadherin
and acquire mesenchymal markers, such as vimentin
and fibronectin [14].
In the present study, we determined the effects of
stable SET knockdown on tumorigenicity using three
HNSCC cell lines, HN12, HN13 and Cal27, in vitro
and the HN12 cell line in vivo (xenograft tumor
models in nude mice). Our studies focused on cell in-
vasion, proliferation, and EMT characteristics, as well
as the in vivo xenograft tumor models, response to cis-
platin, and lymphnode metastasis.
Results
Stable SET knockdown in the HN12 cell line decreases
pERK, p-p53 and p21 expression and increases PP2A
activity with a concomitant reduction in cell proliferation
HN12 cells stably expressing shRNA against SET (shSET)
and control shRNA (shControl) were selected using
puromycin. SET protein knockdown in HN12shSET cells
(Figure 1A) has been maintained for several passages (data
not shown). Using the MTS assay, HN12shSET cell viabil-
ity was 88.6 ± 1.6%, and the viability of HN12 cells with
siRNA for SET was 85.0 ± 2.12%.
To assess the role of SET signaling pathways in HNSCC
cell survival/proliferation, we measured ERK1/2 phosphor-
ylation (pERK 1/2, Figure 1A). Phosphorylated ERK1/2
was reduced in HN12shSET cells, suggesting that SET is
involved in ERK signaling. We also used siRNA as a strat-
egy to temporarily knock down SET protein in HN12 and
Cal27 cells, and a subsequent reduction of pERK 1/2 was
demonstrated (Additional file 1: Figure S1A). PP2A is an
important phosphatase inhibited by SET. We observed
a reduction in the PP2A catalytic (PP2Ac) subunit
by Western blotting (Figure 1A); however, the serine-
threonine phosphatase activity assay indicated increased
PP2A activity in the HN12shSET cells compared with the
HN12shControl cells (Figure 1B). Consistent with this ob-
servation, the BrdU assay indicated reduced proliferation
in the HN12shSET cells compared with the HN12shCon-
trol cells (Figure 1C). Next, we determined whether the
p53 protein was also modified by stable SET knockdown
given that SET is reported to regulate p53 and Akt mRNA
in Alzheimer’s disease [11]. Indeed, Figure 1D shows a re-
duction in p-p53Ser15 and p21 in the HN12shSET cells. In
addition, p53 protein and p-p53Ser15 status was estimated
by Western blotting in HN13 and Cal27 cell lines express-
ing shSET, and a reduction in phosphorylation was ob-
served in both cell lines (Additional file 2: Figure S2). The
total p53 protein level in HN13shSET cells was higher
compared with control while in HN12shSET and Cal27sh-
SET cells the level was not significantly modified. These
data show that the regulation of SET is complex and sug-
gest that each cell line may respond differently to SET
knockdown. Phosphorylation of p53 at Ser-15 and Ser-20
promotes p21 protein transcription followed by cell cycle
arrest at the G0/G1 phase [15]. In this regard, we observed
decreases in number of G0/G1, S, and G2/M phase cells
and an increase in the sub-G1 population of cells for both
the HN12shSET and Cal27shSET cells compared with
their respective controls (Figure 1E).
Stable SET knockdown in HN12 cells promotes the
epithelial-mesenchymal transition (EMT), cell migration,
and invasion
The loss of p53 function is also associated with acquisi-
tion of the mesenchymal phenotype and more aggressive
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Figure 1 ERK and p53 tumor-related protein levels, PP2A phosphatase activity, and proliferation and cell cycle analyses of the HNSCC
shSET cells. (A) Western blotting was performed on HN12 cells using antibodies against SET, pERK1/2, total ERK1/2 and PP2Ac; tubulin was used
as a constitutively expressed protein. (B) PP2A phosphatase activity was determined in HN12 cells using the Ser/Thr Phosphatase Assay system in
the presence or absence of the PP2A inhibitor okadaic acid (OA). (C) Cell proliferation was assessed in HN12 cells using the BrdU incorporation
assay. (D) Western blotting was performed in HN12 cells using antibodies against p53, p-p53Ser15 and p21; β-actin was used as a constitutively
expressed protein. (E) Cell cycle distribution was assessed by PI/flow cytometry in HN12 and Cal27 cells. The results are representative of three
independent experiments. For B and C, the reported values are the mean and standard deviation of experiments performed in triplicate
(*p < 0.05; **p < 0.01). For A and D, the reported values are the shSET/shControl ratio, as described in the Methods section.
Figure 2 EMT markers, cell migration and invasion analyses of the HNSCC shSET cells. (A) Western blotting was performed for SET and the
EMT markers E-cadherin, ZEB2 and vimentin in HN12, HN13 and Cal27 cells; GAPDH was used as a constitutively expressed protein. The values
presented below the bands indicate the shSET/shControl ratio. (B) Immunofluorescence microscopy was used to detect E-cadherin, vimentin and
pan-CTKR proteins in HN12, HN13 and Cal27 cells. (C) The migration assay using the chamber membrane and the invasion through matrigel were
assessed in HN12shControl and HN12shSET cells. The results are either representative of three independent experiments or are reported as the
means and standard deviations of experiments performed in triplicate (*p < 0.05).
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cancer cell migration and invasion [16]. Thus, we dem-
onstrated that stable SET knockdown in the HN12,
HN13 and Cal27 cell lines resulted in down-regulation
of the epithelial marker E-cadherin and up-regulation of
the EMT mediator ZEB2 (Figure 2A). The increase in
the mesenchymal marker vimentin was observed only in
the metastatic HN12 cells (Figure 2A); vimentin was not
observed in HN13 and Cal27 cells. These data reinforce
that the three cell lines studied probably represent differ-
ent types of tumors. Immunofluorescence analysis con-
firmed the reduction of E-cadherin and the increase of
vimentin in the HN12shSET cells (Figure 2B). SET knock-
down using siRNA (a temporary and acute RNAi strategy)
in the HN12 and Cal27 cells reduced E-cadherin level
(Additional file 1: Figure S1A). In contrast to our observa-
tions using stable shSET knockdown, vimentin protein
level did not increase in HN12siSET cells, suggesting that
the effects in vimentin expression are chronic (Additional
file 1: Figure S1A). In addition, we observed the loss of the
epithelial marker pan-CTKR in the HN12, HN13, and
Cal27 shSET cells (Figure 2B), illustrating the role of SET
in EMT in HNSCC. Migration and invasion were studied
only in the metastatic HN12 cell line and a more aggres-
sive potential was identified in the HN12shSET cells
(Figure 2C). The HN12 cells with siRNA-mediated SET
knockdown displayed reduced pan-CTKR (Additional file
1: Figure S1B) and increased invasion compared with the
siRNA control cells (Additional file 1: Figure S1C). This
observation reinforces the view that the action of SET in
the regulation of proteins and processes is related to EMT,
regardless of whether SET knockdown is stable or acute/
temporary. Moreover, our data for the HN12 cell line sug-
gest that increased SET level reduces the aggressive be-
havior of HNSCC cells, despite the fact that increased
SET typically enhances cell proliferation and survival.
We analyzed 84 genes related to cell motility by quanti-
tative real-time PCR. Vimentin, heavy chain non-muscle
myosin (MYH10), and matrix metalloproteinase 9 (MMP-
9) mRNAs were up-regulated in the HN12shSET cells. In
contrast, the protooncogene c-Src (SRC), Wiskott-Aldrich
syndrome-like (WASL) and LIM kinase (LIMK1) mRNAs
were down-regulated (Table 1). Vimentin mRNA up-
regulation was accompanied by an increase in the respect-
ive protein level in HN12shSET cells (Figures 2A and 2B).
The 92 kDa gelatinase B (MMP-9) and 72 kDa gelatinase
A (MMP-2) were evaluated by zymogram. Increased activ-
ity was observed in the HN12shSET cells compared with
control (Figure 3A), particularly when the supernatants
(72 h) were activated with APMA. MMP-9 and MMP-2
were increased 1.7-fold and 5.4-fold, respectively, in
HN12shSET cells (Figure 3B). The active MMP concentra-
tion was estimated by fluorometric assay, and a value of
5.89 μM was obtained for the HN12shSET cells versus
2.47 μM for the HN12shControl cells. These data support
previous findings that indicate a negative correlation be-
tween ERK1/2 activation and MMP-2 activity in HNSCC
tissue samples [17], suggesting that MMPs are modulated
by SET in HNSCC cells.
Cell motility is a complex and dynamic process. The
cofilin protein, a regulator of actin polymerization that
defines the direction of cell motility [18], is phosphory-
lated/inactivated by LIMK1 [19], and LIMK1 mRNA was
down-regulated in the present study (Table 1). In this re-
gard, immunofluorescence analysis using anti-F-actin
and anti-cofilin in HN12shSET cells (Figure 3C) showed
the cytoplasmic accumulation of F-actin and cofilin ag-
gregates compared with control [20]. We suggest that
SET knockdown reduces p21 and consequently modifies
the ROCK/LIMK/cofilin pathway [21], resulting in the
accumulation of F-actin and stress fibers [20]. Increased
migration and invasion through the matrigel can be ex-
plained by this alteration in association with a more rapid
detachment of the HN12shSET cells from the culture dish
than the HN12shControl cells (data not shown) during
trypsin-mediated cell detachment (4 min vs. 10 min, re-
spectively), and increased MMP expression. These findings
suggest that SET is involved in motility, actin dynamics
(accumulation of F-actin and cofilin aggregates in cyto-
plasm), reduced cell adhesion, and increased MMP-9 and
MMP-2 expression. Altogether, these effects confer a more
aggressive phenotype to HN12shSET cells.
Xenograft tumors from the HN12 cell line with stable SET
knockdown in nude mice displayed necrosis, reduced cell
proliferation, and poor differentiation
Next, we assessed the potential action of SET in tumorigen-
icity using HN12shSET xenograft tumors formed in Balb/c
nude mice. The volume of the HN12shSET xenograft tu-
mors was increased compared with the HN12shControl
xenograft tumors (n = 10) (Figures 4A-C). In addition, the
Table 1 mRNA levels of 6 motility genes in the
HN12shSET cells detected by real-time PCR array
Gene Fold up-and down-
regulation
(HN12shSET/HN12shControl)
Up-regulated
Vimentin 2.21
MMP-9 3.26
MYH10 (Myosin, heavy chain,
non-muscle)
5.77
Down-regulated
SRC (V-src sarcoma (Schmidt-Ruppin −2.28
A-2) viral oncogene homolog (avian))
WASL Wiskott-Aldrich syndrome-like −2.28
LIMK1 (LIM domain kinase 1) - −2.73
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macroscopic characteristics of the tumors were different.
The HN12shControl xenograft tumors (4 weeks after cell
injection) contained a solid, white, homogeneous mass,
whereas the HN12shSET tumor resembled a large cyst
comprised of friable tissues and fluids (Figures 4B and
4C). In addition, expression of the proliferative marker
Ki67 was reduced in the HN12shSET xenograft tumors
compared with the control tumors (Figure 4D), in
agreement with the reduced proliferative index mea-
sured in vitro by the BrdU assay (Figure 1C).
Accordingly, histological analysis (Figure 5) demon-
strated that the HN12shControl tumors were well-
Figure 4 Characteristics of the HN12shSET xenograft tumors formed in nude mice. (A) Images of tumors formed from HN12shSET cells
implanted in the flanks of Balb/c nude mice (n = 10). (B) The HN12shControl cells formed a solid tumor, whereas the HN12shSET tumors were
similar to a large cyst and contained a yellow-white necrotic liquid that was visible when the tumors were cut. Representative images of tumors
4 weeks after cell injection are presented. (C) The volume of the tumors formed by HN12shSET cells. (D) The number of Ki67-positive tumor cells,
determined as described in the Methods section. The data are reported as the means and standard deviations (*p < 0.05).
Figure 3 Metalloproteinase (MMP-9 and MMP-2) activity as well as cofilin and F-actin expression in the HNSCC shSET cells. (A)
Zymogram analysis using MMP secreted from HN12shSET cells at 24 and 72 h. (B) Zymogram analysis was performed in the presence of 1 mM
APMA for 1 h at 37°C. The values indicated below the bands represent the shSET/shControl ratio of MMP activity. (C) Immunofluorescence
analysis of F-actin (red) and cofilin (green), demonstrating the expression and distribution pattern of F-actin and cofilin; nuclei were stained with
DAPI (blue). Arrows indicate cofilin aggregates in the cytoplasm. The results are representative of three independent experiments.
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differentiated and produced keratin (Figure 5A). In
contrast, the HN12shSET tumors were poorly differen-
tiated and presented extensive liquefactive necrotic
areas (Figure 5A). The HN12shSET tumors displayed an
inflammatory infiltrate (Figure 5B-a), increased blood
microvessel density (Figure 5B-b), atypical mitoses, and
anaplastic cells (Figure 5B).
Immunohistochemistry (IHC) analysis confirmed SET
protein knockdown in the HN12shSET xenograft tumor
cells (Figure 6A). The HN12shSET xenograft tumor also
showed a loss of pan-CTKR, indicative of poor differenti-
ation, and reduced p62 protein (Figure 6A). In this regard,
a weak p62 protein staining suggests reduced proliferation
[22] and autophagy [23,24]. E-cadherin and vimentin were
analyzed by Western blotting in the HN12shSET and
HN12shControl xenograft tumors (Figure 6B). E-cadherin
protein level was significantly reduced (Figure 6C) and
vimentin protein level was increased (Figure 6D). In
addition, the HN12shSET xenograft tumor showed
reduced p53Ser-15 and ERK1/2 phosphorylation levels
(Additional file 3: Figure S3).
HN12shSET xenograft tumor models are cisplatin
sensitive and display lymph node metastasis, not
observed in HN12shControl xenograft tumors
The potential of the SET protein as a new target in can-
cer therapy has been explored using a peptide [25] and
sphingolipid (FTY720) [26] to disrupt the SET-PP2A
interaction [27]. In the present study, we assessed SET
knockdown in combination with cisplatin chemotherapy.
Nude mice with HN12shSET and HN12shControl xeno-
graft tumors (n = 5) were treated with cisplatin (Figure 7).
The HN12shSET xenograft tumors were sensitive to cis-
platin treatment, presenting frequent ulcerated skin le-
sions and tumor cell death (black tissue; Figure 7A and
7B). In contrast, the HN12shControl xenograft tumors
were not affected by cisplatin treatment.
An orthotopic tongue xenograft tumor model in nude
mice (n = 3) was adopted to evaluate the metastatic
potential of the HN12shSET cells compared with the
HN12shControl cells. Two out of three animals were
lymph node positive in the HN12shSET orthotopic tumor
model, and no mice were positive in the HN12shcontrol
model (Figure 8).
Discussion
SET is associated with many cellular processes, such as
cell cycle control [28], apoptosis [29], migration [30,31],
DNA damage repair [32], and chromatin remodeling
[33]. Recently, we demonstrated that SET extensively ac-
cumulates in HNSCC and is involved with the oxidative
stress response [34]. In the present study, we addressed
the effects of stable SET knockdown on tumorigenicity
in HNSCC. Unexpectedly, we found that the HN12 cells
Figure 5 Histological analysis of the HN12shSET xenograft tumors. Representative images of HN12shSET xenograft tumors sections stained
with H&E. (A) The HN12shSET cells formed a poorly differentiated tumor with reduced keratin pearl formation and liquefactive necrotic areas
(black arrows), along with viable tumor cells (white arrows). (B) The HN12shSET tumors showed atypical mitoses, anaplastic cells and
hemorrhages. The inserts show an inflammatory infiltrate (a) and increased blood microvessel density (b). Asterisks (*) indicate microvessels.
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Figure 6 SET, PAN-CTKR, p62, E-cadherin and vimentin expression in the HN12shSET xenograft tumors. (A) Immunohistochemical
analysis shows a reduction of SET, PAN-CTKR and p62 protein expression in the HN12shSET tumor xenografts compared with the HN12shControl
tumors. (B) Western blotting of proteins extracted from the HN12shSET xenograft tumors. The semiquantitative analysis using densitometry
confirmed reduction of the amount of E-cadherin (C) and increase of vimentin (D) protein expression compared with the shControl tumors. The
bars indicate the mean and standard deviation of values obtained by densitometric analysis (*p < 0.05).
Figure 7 Cisplatin sensitivity in the HN12shSET xenograft tumors. Xenograft tumors were formed from the HN12shSET cells implanted in
Balb/c nude mice as described in the Methods section. (A) Mice were euthanized ten days after the final cisplatin treatment (3.5 mg/kg/day, i.p.,
for 5 days), and (B) the tumors were dissected.
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became more invasive and presented a mesenchymal-
like phenotype with reduced proliferation after stable
SET knockdown; in addition, the HN12shSET xenograft
tumors were sensitive to cisplatin chemotherapy. This is
the first demonstration of the action of SET on the EMT
using both in vitro and in vivo models, and these find-
ings reinforce SET’s potential as a therapeutic target in
HNSCC. Furthermore, the development of an orthotopic
HN12shSET xenograft tumor model confirmed the gain
of a mesenchymal-like behavior.
Previous reports have demonstrated the effects of a
sphingolipid pharmacological inhibitor (FTY720) in lung
cancer [26] and chronic myeloid leukemia [35] models.
The antitumor action of FTY720 was associated with in-
creased PP2A activity via specific inhibition of the nuclear
SET-PP2A interaction, resulting in necroptosis [26]. The
action of this pharmacological inhibitor was based on an
acute condition and potent PP2A activation [27,36]. In this
regard, SET could be therapeutically targeted to activate
PP2A and improve tumor cell therapies. In the present
study, we selected stable HNSCC cell lines with chronic
SET knockdown, displaying an approximate 70% reduction
in SET protein. SET knockdown was accompanied by up-
regulation of PP2A activity and down-regulation of pERK
and p-p53. Moreover, the mutated p53 gene has been cor-
related with enhanced cisplatin sensitivity via inactivation
of the p53 pathway [37], consistent with our observations
in the HN12shSET cells. Additionally, cisplatin cytotoxicity
is associated with reactive oxygen species production
[38,39], and SET was previously proposed to be a sensor of
oxidative stress that promotes cell survival in HNSCC [34].
Our results suggest that SET knockdown significantly
alters HN12 cell sensitivity to cisplatin-mediated death
in vivo. Importantly, an inflammatory infiltrate and
necrosis were evident in the HN12shSET xenograft tu-
mors, suggesting that SET accumulation in HNSCC
plays an important role in cell survival in vivo.
In numerous solid tumors, metastasis is preceded by
EMT, which allows cells to repress epithelial characteris-
tics and to acquire a mesenchymal-like phenotype that is
associated with increased migration and invasion [13].
An association between p53 inactivation and the EMT, as
well as a p53-mediated EMT checkpoint, has been pro-
posed in various cancer types [12,40]. In this study, SET
knockdown in HN12 cells promoted a mesenchymal-like
phenotype. Moreover, SET knockdown in HN12 cells up-
Figure 8 The orthotopic HN12shSET xenograft tumor model and lymph node metastasis. (A) Images of the tumors formed by the
HN12shControl and HN12shSET cells in the tongue of Balb/c nude mice. After fifteen days, the animals were euthanized, and the tongue and
lymph nodes were dissected. (B) Histopathological analysis of the orthotopic HN12shControl and shSET H&E-stained xenograft tumor sections.
(C) Histopathological analysis of the cervical lymph nodes from the orthotopic HN12shSET xenograft tumor revealed the presence of metastatic
cells 15 days after injection, whereas the lymph nodes in mice bearing HN12shControl xenograft tumors lacked metastatic cells.
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regulated MMP-9 and MMP-2 expression (collagenase)
and altered the actin dynamic, which is important for mi-
gration and invasion [20,41]. These results suggest that
SET accumulation in HNSCC promotes tumor growth
while limiting cell migration and invasion. The orthotopic
human xenograft tumor model showed increase of metas-
tasis in HN12shSET cells compared with HN12shControl.
Therefore, SET-mediated actions, including the classical
action of increase PP2A activity that was also observed in
the HN12shSET cells, may contribute to both HNSCC
progression and cell differentiation in vitro and in vivo.
Conclusions
(1) SET accumulation has important actions in HNSCC:
as an oncogene, SET promotes cell proliferation, sur-
vival, and resistance to cell death by cisplatin in vivo; as
a metastasis suppressor, SET regulates invasion, the epi-
thelial mesenchymal transition, and metastasis. (2) This
is the first time a functional response initiated exclu-
sively by shRNA-mediated stable knockdown of SET is
achieved in cancer. (3) The stable SET knockdown stan-
dardized in this study may serve as a model to evaluate
the effects of SET reduction and the mechanisms related
to aggressive cancer behaviors.
Methods
The Animal Care and Use Committee of the University of
São Paulo (Ribeirão Preto Campus) approved the proce-
dures used in this study (protocol numbers 11.1.168.53.2
and 11.1.193.53.7).
Cell culture and HNSCC cell lines with SET-knockdown
The HNSCC cell lines HN12 (tumorigenic and meta-
static), HN13 [42] and Cal27 (ATCC, Manassas, VA, USA)
were cultured in Dulbecco’s modified medium (DMEM,
Sigma-Aldrich, Munich, Germany), supplemented with
10% fetal bovine serum (FBS, GIBCO, Carlsbad, CA,
USA), antibiotics and antimycotics (Sigma-Aldrich) in a
humidified atmosphere of 5% CO2 at 37°C. The MISSION
short-hairpin RNA (shRNA) plasmid TCR1 containing
DNA against human SET (shSET; TRCN0000063717;
NM_003011.1-467s1c1; Sigma-Aldrich) or the shRNA
control (shControl; pLKO.1puro; SHC002, shRNA non-
mammalian target; Sigma-Aldrich) were transfected
into HN12 cells using the Turbofect reagent (Thermo,
Chelmsford, Massachusetts, USA). Stable transfectants
were selected using puromycin (1 μg/mL). Lentivectors
containing the shSET and shControl constructs were
added to the HN13 and Cal27 cells for transduction.
The transduced cells were selected using puromycin
(1 μg/mL). For siRNA expression in the HNSCC cell
lines, duplex RNA (siRNA) against SET was purchased
from Qiagen; the protocol used for this experiment was
previously reported [34]. The efficacy of SET knock-
down was evaluated by Western blotting.
Western blotting
Cell protein extracts were obtained using the CelLytic
Mammalian Cell Lysis/Extraction Reagent (Sigma-Aldrich)
with protease and phosphatase inhibitor cocktails (Sigma-
Aldrich). Protein concentration was determined using the
Bradford protein assay (Bio-Rad Laboratories, Hercules,
CA, USA). Thirty micrograms of protein were separated
by 10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to a PVDF
membrane (GE HealthCare, Freiburg, Germany). The
membranes were blocked in 5% non-fat dry milk in
Tris-buffered saline containing 10% Tween 20. Anti-
bodies against SET (E15; #sc-5655; Santa Cruz), ERK1/2
(M 5670; Sigma-Aldrich), phospho-p44/42 MAPK
ERK1/2 (pERK1/2; #4377; Cell Signaling, Rockford, IL,
USA), PP2Ac (PP2A catalytic subunit; #2038; Cell Sig-
naling), p53 (7 F5; #2527; Cell Signaling), phospho-p53
(p-p53Ser15; #9286; Cell Signaling), p21WAF1/Cip1
(12D1; #2974; Cell Signaling), β-actin and tubulin were
used. The reactions were developed using the chemilu-
minescent ECL Western blotting system (GE Health-
Care). Densitometric analysis was performed using the
ImageJ 6.4 software [43], and bands were normalized to
constitutive proteins. The values are presented as the
shSET/shControl ratio. For phosphorylation analysis,
the phosphorylated/total protein ratio was calculated,
and representative values are presented.
Cell viability assay
The CellTiter 96® AQueous One Solution Cell Prolifera-
tion Assay (Promega, Madison, WI, USA) was used to
determine cell viability according to the manufacturer’s
instructions. The assays were performed in quintupli-
cate, and three independent biological experiments were
considered. The cells were plated on 96-well plates 24 h
before the addition of the MTS solution (tetrazolium
compound and phenazine methosulfate). Next, the cells
were incubated for 2 h, and the absorbance at 490 nm
was recorded using a microplate reader (Bio-Rad).
Cell proliferation assay
Cell proliferation was estimated using the bromodeoxyuri-
dine (BrdU; Sigma-Aldrich) incorporation index as previ-
ously reported [44], with modifications. In addition, the
mouse monoclonal anti-BrdU BU 33 antibody (cat. #2531;
Sigma-Aldrich) was used, and IHC staining was per-
formed using the DAKO LSAB + System-HRP kit (DAKO,
Carpinteria, CA, USA). The BrdU-labeling index, reported
as the percentage of cells labeled with BrdU, was deter-
mined by counting 10,000 cells from two independent re-
actions using the Zeiss Axiovert 40 inverted microscope
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and the AxioVision Rel. 4.8.2 software (Carl Zeiss, New
York, USA).
Cell cycle assay
The cell cycle was analyzed by flow cytometry using pro-
pidium iodide (PI; Sigma). Twenty-four hours after re-
lease from synchrony, the cells were maintained for an
additional 24 h in DMEM 10% FBS. Next, the cells were
collected and fixed in 70% ethanol. After washing in PBS
and centrifugation, the cells were suspended in the PI
(50 μg/mL) solution containing DNase-free RNAse (Invi-
trogen) and maintained for 30 min at 37°C. The assay was
performed in a Guava® easyCyte™ 8HT flow cytometry
system, and the InCyte 2.2 software (Merck Millipore,
Darmstadt, Germany) was used for acquisition and
analysis.
Migration and invasion assays
The in vitro cell migration and invasion assays were
performed in 24-well plates (Corning, Inc., New York,
USA) using modified Boyden chamber inserts with a
polycarbonate filter membrane containing 8-μm pores.
For the invasion assay, matrigel (BD Biosciences) was di-
luted 1:1 with serum-free medium and used to coat the
filter membranes. The cells (1×105) were suspended in
250 μl of serum-free DMEM and seeded onto the upper
compartment of the transwell chamber; DMEM contain-
ing 10% FBS was used in the lower chamber for stimula-
tion. After a 24 h or 72 h incubation for the migration
or invasion analysis, respectively, the medium in the
upper chamber was removed, and the filters were fixed
in 10% formalin for 15 min. The cells on the lower sur-
face were stained with 4′, 6-diamidino-2-phenylindole
(DAPI; Sigma). Five fields were photographed at ×200
original magnification using a Zeiss Axiovert 40 inverted
microscope and processed using the AxioVision Rel.
4.8.2 software. The cells were counted using the ImageJ
program [43]. The migration and invasion data are re-
ported as the number of cells per microscopic field. Five
fields were analyzed.
Quantitative real time PCR array
RNA isolation and cDNA synthesis were performed
using the RNeasy and RT2 First Strand kits (Qiagen,
Hilden, Germany), respectively. Total cDNA was used
to quantify the mRNAs of 84 human genes related to
cell motility in a 96-well plate array (Human Cell Motil-
ity RT2 Profiler™ PCR Array System, PAHS-128A-12,
SABiosciences, Frederick, MD, USA) according to the
manufacturer’s instructions for the Eppendorf Master-
cycler EP Realplex instrument (Eppendorf, Hamburg,
Germany). Up-and down-regulated genes were defined
as genes with expression levels in HN12shSET cells that
are >2.0 or < −2.0, respectively, [45] in relation to the
HN12shControl cells. These analyses were performed in
triplicate. The calculation was performed using the RT2
Profiler PCR Array Data Analysis, version 3.5.
Immunofluorescence analysis
Immunofluorescence was performed with primary anti-
bodies against E-cadherin (24E10; #3195; Cell Signaling),
pan-cytokeratin (pan-CTKR; ab6401; Abcam), cofilin
(#3312; Cell Signaling), F-actin (NH3; MA1-80729;
Thermo-Scientific), β-actin (C4: sc-47778; Santa Cruz),
and vimentin (Clone V9; V6389; Sigma). Cells were in-
cubated with either an anti-rabbit antibody conjugated
with Alexa 488 or an anti-mouse antibody conjugated
with Alexa 594 (Invitrogen). The nuclei were stained
with DAPI. The digital images were obtained using a
Zeiss Axiovert 40 inverted microscope and processed
using the AxioVision Rel. 4.8.2 software (Carl Zeiss).
Zymographic analysis of matrix metalloproteinases
Cells (3×105) were plated in a 6-well plate in triplicate.
After 24 h, the medium was changed to DMEM without
fetal bovine serum (FBS), and the cells were maintained
for an additional 24 h and 72 h. The supernatant was
collected from three wells and concentrated in an Amicon
Ultra Centrifugal Filter Device 10,000 MWCO (Millipore,
UFC901024). The cells were then counted. Ten microli-
ters of concentrated supernatant was activated with 1 mM
4-aminophenylmercuric acetate (APMA; Sigma-Aldrich)
for 1 h at 37°C or not treated. The samples were resolved
by 12% SDS-PAGE containing 1 mg/mL gelatin. The gel
was washed with 2% Triton X-100 for 40 min and incu-
bated in a reaction buffer containing 10 mM Tris–HCl,
pH 8.0, and 5 mM CaCl2 for 16 h at 37°C. The gel was
then stained with 0.25% Coomassie blue. After removing
the stain, the negative bands representing the MMP activ-
ity were visualized. Semiquantitative analysis using densi-
tometry was performed with the ImageJ 6.4 software [43].
The results are reported as the shSET/shControl ratio.
Fluorometric matrix metalloproteinase assay
The molar concentration of active matrix MMP in the
cell culture supernatants was determined by active-site
titration using the inhibitor phosphoramidon and the
method of Klemencic et al. [46] with modifications. An
inhibitor cocktail containing E-64 (cat. #E3132; Sigma-
Aldrich), PMSF (cat. #78830; Sigma-Aldrich), and pepsta-
tin (cat. #77170; Sigma-Aldrich) was used. The reaction
mixture contained 1.9 mL of 30 mM Tris–HCl, pH 8.0,
the inhibitor cocktail (10 μM final concentration), and the
supernatant from the cell cultures. After incubation for
2 min at 37°C, the fluorogenic peptide substrate Abz-
KLRSYKQ-EDDnp (25 μM) was added. Substrate hydroly-
sis was monitored using a spectrofluorometer model
Lumina fluorescence spectrometer (Thermo Scientific) at
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λex = 320 nm and λem = 420 nm. The inhibitor phosphor-
amidon (Sigma-Aldrich) was added until total enzyme in-
hibition was achieved.
Serine/threonine phosphatase assay
Threonine phosphatase-2A (PP2A) activity was mea-
sured using the Serine/Threonine Phosphatase Assay
system (Promega; V2460) and the synthetic peptide RRA
(pT)VA (Promega). For this assay, cells were lysed with
Cellytic (Sigma) containing a protease inhibitor cocktail
(Sigma), and the free phosphate was eliminated from the
lysates using a Sephadex G-25 resin (Promega). For mea-
surements of phosphatase activity, a standard phosphate
curve was first constructed with 0, 100, 200, 500, 1,000
and 2,000 ρmol of phosphate. The samples (2.5 μg of
total protein) were incubated with or without 12 nM or
5 μM okadaic acid for 15 minutes at room temperature.
The reaction was performed by adding the PP2ase-2A 5×
reaction buffer (250 mM imidazole, pH 7.2, 1 mM EGTA,
0.1% β-mercaptoethanol, 0.5 mg/ml bovine serum albu-
min) and the Thr phosphopeptide to the samples in a 96-
well plate for 10 minutes at 30°C. The reaction was
stopped by incubation with the molybdate dye for 15 mi-
nutes, and the absorbance was determined at 595 nm
using a microplate reader (BioRad).
Tumorigenicity and immunohistochemistry assays
To assess the xenograft tumor growth, 2×106 HN12shCon-
trol and HN12shSET cells were injected s.c. into the left
and right flanks, respectively, of ten 8-week-old Balb/C
male nude mice. The tumor size was measured weekly
using a caliper; the volume was reported as mm3 and cal-
culated using the formula 0.5 × length × width2. At 4 weeks
post-injection, the mice were euthanized. The tumors were
collected, fixed in 10% formalin, and embedded in paraffin.
Five-μm sections were stained with H&E for histological
analysis. Three-μm sections were used for the immunohis-
tochemical analysis of SET, Ki67, pan-CTKR, p62, pERK1/
2, and p-p53Ser15 proteins as previously described [5]. The
following primary antibodies were used: Ki67 (ab15580;
Abcam, Cambridge, England), p62/SQSTM1 (D-3: sc-
28359; Santa Cruz Biotechnologies, Santa Cruz, CA, USA),
pan-CTKR, SET, pERK1/2 and p-p53Ser15. For Ki67 ana-
lysis, five microscopic fields were analyzed for the deter-
mination of percentage of positive cells.
Cisplatin treatment of Balb/c nude mice bearing HN12
xenograft tumors
To evaluate cisplatin sensitivity in vivo, five Balb/C nude
mice were injected with cells as described above. Cis-
platin was administered intraperitoneally at 3.5 mg/kg/
day (Platinil 50 mg/100 mL; Quiral Química do Brasil)
15 days after cell injection, and the treatment continued
for 5 days. The post-treatment procedures are the same
as described above.
An orthotopic HN12 human xenograft tumor model for
analysis of lymph node metastasis
We used an orthotopic human xenograft tumor model to
evaluate metastatic potential. The stable SET knockdown
HN12 (HN12shSET) and HN12shControl cells (2 × 105)
were injected into the tongues of Balb/c nude mice after
anesthesia (n = 3) according to the ethical conduct out-
lined in the Care and Use of Animals for Experimentation
of the University of São Paulo. The mice were assessed
daily and weighed once a week. The mice were euthanized
15 days post-injection. The tongue and lymph nodes were
collected, fixed in 10% formalin, and embedded in paraf-
fin. Five-μm sections were stained with H&E for histo-
logical analysis.
Statistical analysis
Statistical analysis was performed using Student’s t test,
and the results are reported as the means ± standard de-
viations. P values <0.05 are considered to be statistically
significant.
Additional files
Additional file 1: Figure S1. Temporary/acute SET knockdown using
siRNA in HNSCC cells: reduced pERK and E-cadherin expression in HN12
and Cal27 cells, and reduced pan-CTKR as well as increased invasive
ability in HN12 cells. The experiments were performed 48 h after SET
siRNA transfection. (A) Western blotting using antibodies against SET, total
ERK1/2, pERK1/2, E-cadherin, vimentin and tubulin (as a constitutively
expressed protein). The densitometric results are presented as the shSET/
shControl ratio. ERK phosphorylation is indicated as phospho-ERK/total ERK.
(B) Immunofluorescence using an anti-pan-CTKR in HN12siSET cells; nuclei
were stained with DAPI (blue). (C) HN12 cells with SET knockdown
(HN12siSET) and negative siRNA control cells in the matrigel invasion assay.
The results are either representative of three independent experiments or
are reported as the means and standard deviations of
experiments performed in triplicate (*p < 0.05).
Additional file 2: Figure S2. Reduction of p-p53Ser-15 in HN13 and
Cal27 cell lines with stable SET knockdown (shRNA). Western blotting was
performed using antibodies against total p53, p-p53Ser-15 and tubulin. The
densitometric values represent the shSET/shControl ratio. Tubulin was
used as a constitutively expressed protein.
Additional file 3: Figure S3. Reduction of p-p53 and pERK in the
HN12shSET xenograft tumors compared with HN12shControl tumors.
Three-μm sections from the HN12shSET xenograft tumors were used for
immunohistochemical analysis with antibodies against p-53Ser-15 and
pERK1/2. The images are representative of three experiments. The
immunocomplexes were visualized with a chromogenic substrate (DAB;
brown) and counterstained with hematoxylin.
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